About this trial

Postpartum hemorrhage (PPH) is the global leading cause of maternal death, with 20-30% of maternal deaths in Thailand linked to hemorrhage. The WOMAN Trial (2017) provided strong evidence that administering tranexamic acid (TXA)within three hours of bleeding onset lowered PPH-related mortality by 31%. Consequently, the World Health Organization (WHO) updated its guidelines, recommending TXA as part of the standard treatment package for all PPH cases. Following this, the use of TXA has been widely adopted globally and increased in Thailand. A recent study at a major Thai university hospital observed a significant increase in TXA administration after 2017. The current study aims to further analyze the recent growth rate of TXA use and its impact on obstetric and perinatal outcomes during cesarean deliveries with PPH.

Eligibility criteria

Qualifiers

1. Patients underwent cesarean delivery with primary postpartum hemorrhage

Disqualifiers

Gestational age at less than 24 weeks

Absence of the anesthetic record

Received tranexamic acid in the antepartum period

Blood loss less than 1,000 ml

Trial design

Treatments tested in this trial

  • Tranexamic acid

Treatment groups

648 Participants
are divided into 2 treatment groups

Locations

1
Siriraj Hospital10700, BangkoknoiBangkok, Thailand

Sponsors and collaborators

Mahidol University

Lead sponsor